Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR? primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; ?to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.

Abstract: There is provided herein, a texaphyrin-phospholipid conjugate, wherein the texaphyrin-phospholipid conjugate comprises a texaphyrin, texaphyrin derivative or texaphyrin analog covalently attached to a lipid side chain of a phospholipid.

Abstract: The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullination of proteins by peptidyl arginine deiminase (PAD) enzymes.

Abstract: Provided are methods and products for obtaining cardiovascular lineage cells from hPSCs.

Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.

Abstract: A method and apparatus is provided to iteratively reconstruct a computed tomography (CT) image using a spatially-varying content-oriented regularization parameter, thereby achieving uniform statistical properties within respective organs/regions and different statistical properties (e.g., degree of smoothing and noise level) among the respective organs/regions. For example, less smoothing and sharper features/resolution can be applied within a lung region than within a soft-tissue region by using a smaller regularization parameter value in the lung region than in the soft-tissue region. This can be achieved, e.g., using a minimum intensity projection to suppress/eliminate sub-solid nodules in the lung region. The content-oriented regularization parameter can be generated by reconstructing an initial CT image, which is then segmented/classified according to organs and/or tissue type.

Abstract: A method and apparatus is provided to iteratively reconstruct a computed tomography (CT) image using a spatially-varying content-oriented regularization parameter, thereby achieving uniform statistical properties within respective organs/regions and different statistical properties (e.g., degree of smoothing and noise level) among the respective organs/regions. For example, less smoothing and sharper features/resolution can be applied within a lung region than within a soft-tissue region by using a smaller regularization parameter value in the lung region than in the soft-tissue region. This can be achieved, e.g., using a minimum intensity projection to suppress/eliminate sub-solid nodules in the lung region. The content-oriented regularization parameter can be generated by reconstructing an initial CT image, which is then segmented/classified according to organs and/or tissue type.

Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: Methods for quantifying fluorescence and optical properties in a turbid medium such as tissue. Devices and systems suitable for the methods are also disclosed.

Abstract: Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.

Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: Systems and methods for obtaining diagnostic data of a target are disclosed. The systems include an imaging device and a drape. The imaging device includes at least one excitation light source for fluorescent imaging, and an optical sensor configured to detect signals responsive to illumination of the target with the excitation light. The drape is configured to reduce ambient light surrounding the target during imaging.

Abstract: Various embodiments are described herein for a system and a method for treatment planning for providing ablative therapy to a patient. The treatment planning may involve segmenting images of the patient to define areas to receive treatment, defining trial parameters, simulating treatment of ablative therapy to the patient according to the trial parameters; analyzing a thermal dose distribution resulting from the simulated treatment to determine treatment effectiveness; determining when the treatment effectiveness meets a treatment effectiveness criteria; and providing an indication of the trial parameters when the treatment effectiveness meets the treatment effectiveness criteria.

Abstract: A Radio-Therapy (RT) system includes an integrated radiation source and a Magnetic Resonance Imaging (MRI) system that implements a method for providing a variable imaging Field Of View (FOV). The FOV can be tailored for various RT-specific applications such as, but not limited to, patient setup verification and real-time tumor tracking, for example, as well as for various imaging volumes of interest.

Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): (Formula (I)) wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: Methods, devices and systems for quantifying fluorescence and optical properties in a turbid medium such as tissue are disclosed. One of the methods comprises: providing fluorescence emission and reflectance wavelengths detected from a target surface where each of the detected wavelengths is associated with a respective known distance between a respective excitation source giving rise to the respective detected wavelength and a detector detecting the respective detected wavelength; and calculating the optical properties based on the detected wavelengths and the respective known distances. The known distances may be predetermined to enable calculation of a desired range of values for the optical properties. The calculation of the optical properties may be based on a model of light interaction with the turbid medium where the model limits a range of calculated values for the optical properties.